van Oirschot Pim, Heerings Marco, Wendrich Karine, den Teuling Bram, Dorssers Frank, van Ee René, Martens Marijn Bart, Jongen Peter Joseph
Orikami Digital Health Products, Nijmegen, Netherlands.
Dutch National Multiple Sclerosis Foundation, Rotterdam, Netherlands.
JMIR Form Res. 2021 Nov 17;5(11):e29128. doi: 10.2196/29128.
Walking disturbances are a common dysfunction in persons with multiple sclerosis (MS). The 2-Minute Walking Test (2MWT) is widely used to quantify walking speed. We implemented a smartphone-based 2MWT (s2MWT) in MS sherpa, an app for persons with MS. When performing the s2MWT, users of the app are instructed to walk as fast as safely possible for 2 minutes in the open air, while the app records their movement and calculates the distance walked.
The aim of this study is to investigate the concurrent validity and test-retest reliability of the MS sherpa s2MWT.
We performed a validation study on 25 persons with relapsing-remitting MS and 79 healthy control (HC) participants. In the HC group, 21 participants were matched to the persons with MS based on age, gender, and education and these followed the same assessment schedule as the persons with MS (the HC-matched group), whereas 58 participants had a less intense assessment schedule to determine reference values (the HC-normative group). Intraclass correlation coefficients (ICCs) were determined between the distance measured by the s2MWT and the distance measured using distance markers on the pavement during these s2MWT assessments. ICCs were also determined for test-retest reliability and derived from 10 smartphone tests per study participant, with 3 days in between each test. We interviewed 7 study participants with MS regarding their experiences with the s2MWT.
In total, 755 s2MWTs were completed. The adherence rate for the persons with MS and the participants in the HC-matched group was 92.4% (425/460). The calculated distance walked on the s2MWT was, on average, 8.43 m or 5% (SD 18.9 m or 11%) higher than the distance measured using distance markers (n=43). An ICC of 0.817 was found for the concurrent validity of the s2MWT in the combined analysis of persons with MS and HC participants. Average ICCs of 9 test-retest reliability analyses of the s2MWT for persons with MS and the participants in the HC-matched group were 0.648 (SD 0.150) and 0.600 (SD 0.090), respectively, whereas the average ICC of 2 test-retest reliability analyses of the s2MWT for the participants in the HC-normative group was 0.700 (SD 0.029). The interviewed study participants found the s2MWT easy to perform, but they also expressed that the test results can be confronting and that a pressure to reach a certain distance can be experienced.
The high correlation between s2MWT distance and the conventional 2MWT distance indicates a good concurrent validity. Similarly, high correlations underpin a good test-retest reliability of the s2MWT. We conclude that the s2MWT can be used to measure the distance that the persons with MS walk in 2 minutes outdoors near their home, from which both clinical studies and clinical practice can benefit.
行走障碍是多发性硬化症(MS)患者常见的功能障碍。2分钟步行测试(2MWT)被广泛用于量化步行速度。我们在MS sherpa(一款针对MS患者的应用程序)中实施了基于智能手机的2MWT(s2MWT)。在进行s2MWT时,该应用程序的用户被指示在户外尽可能安全地快走2分钟,同时应用程序记录他们的运动并计算行走的距离。
本研究的目的是调查MS sherpa s2MWT的同时效度和重测信度。
我们对25例复发缓解型MS患者和79名健康对照(HC)参与者进行了一项验证研究。在HC组中,21名参与者根据年龄、性别和教育程度与MS患者匹配,并与MS患者遵循相同的评估时间表(HC匹配组),而58名参与者有一个不太密集的评估时间表以确定参考值(HC规范组)。在这些s2MWT评估期间,确定s2MWT测量的距离与使用人行道上的距离标记测量的距离之间的组内相关系数(ICC)。还确定了s2MWT的重测信度的ICC,每个研究参与者进行10次智能手机测试,每次测试间隔3天。我们采访了7名MS研究参与者关于他们使用s2MWT的体验。
总共完成了755次s2MWT。MS患者和HC匹配组参与者的依从率为92.4%(425/460)。s2MWT上计算出的行走距离平均比使用距离标记测量的距离高8.43米或5%(标准差18.9米或11%)(n = 43)。在MS患者和HC参与者的综合分析中,s2MWT的同时效度的ICC为0.817。MS患者和HC匹配组参与者的s2MWT的9次重测信度分析的平均ICC分别为0.648(标准差0.150)和0.600(标准差0.090),而HC规范组参与者的s2MWT的2次重测信度分析的平均ICC为0.700(标准差0.029)。接受采访的研究参与者发现s2MWT易于执行,但他们也表示测试结果可能会令人不安,并且可能会感受到达到一定距离的压力。
s2MWT距离与传统2MWT距离之间的高度相关性表明具有良好的同时效度。同样,高相关性支持了s2MWT良好的重测信度。我们得出结论,s2MWT可用于测量MS患者在家附近户外2分钟内行走的距离,临床研究和临床实践均可从中受益。